Cart
sales@molnova.com
GSK-2838232
CAS No. 1443460-91-0
GSK-2838232 ( GSK2838232 )
Catalog No. M11882 CAS No. 1443460-91-0
GSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 125 | Get Quote |
|
| 10MG | 200 | Get Quote |
|
| 25MG | 439 | Get Quote |
|
| 50MG | 641 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK-2838232
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.
-
DescriptionGSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.HIV Infection Phase 2 Clinical
-
SynonymsGSK2838232
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research AreaInfection
-
IndicationHIV Infection
Chemical Information
-
CAS Number1443460-91-0
-
Formula Weight809.57
-
Molecular FormulaC48H73ClN2O6
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 50 mg/mL 61.76 mM
-
SMILESO=C(O)C(C)(C)CC(O[C@@H](CC[C@]1(C)[C@@]2([H])CC[C@@]34[H])C(C)(C)[C@]1([H])CC[C@@]2(C)[C@]3(C)CC[C@]5([C@@H](O)CN(CC6=CC=CC(Cl)=C6)CCN(C)C)C4=C(C(C)C)C(C5)=O)=O
-
Chemical Name(3b)-3-(3-Carboxy-3-methyl-1-oxobutoxy)-17-[(1R)-2-[[(4-chlorophenyl)methyl][2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-28-norlup-18-en-21-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Enfuvirtide
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection.
-
I-XW-053
I-XW-053 is an inhibitor of capsid targeted HIV-1 replication using the hybrid structure based method to block the interface between CA N-terminal domains (NTD-NTD interface) with micromolar affinity.
-
Decanoyl-RVKR-CMK
Subtilisin/Kex2p-like proprotein convertase inhibitor; blocks activity of all seven convertases (PC1, PC2, PC4, PACE4, PC5, PC7 and furin). Abolishes proET-1 processing in endothelial cells; inhibits regulated secretion of the neuronal polypeptide VGF in PC12 cells.
